Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6071709 | 0.93 | SLC18A3 (0.50) | HSD11B1SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6071356 | 0.78 | MGLL (0.48) | MGLLHSD11B1SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6072177 | 0.78 | MGLL (0.48) | MGLLHSD11B1SLC18A3 | |
| SCHEMBL6072180 | 0.72 | HSD11B1 (0.62) | MGLLHSD11B1SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6072250 | 0.70 | SLC18A3 (0.50) | HSD11B1SLC18A3ALDH1A1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4463464 | 0.70 | SLC18A3 (0.50) | HSD11B1SLC18A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6212091 | 0.68 | MGLL (1.00) | MGLLHSD11B1 | |
| SCHEMBL3111417 | 0.66 | CHRNB2 (0.46) | MGLLSLC18A3ALDH1A1 | |
| SCHEMBL13157699 | 0.66 | CHRNB2 (0.46) | MGLLSLC18A3ALDH1A1 | |
| SCHEMBL5472341 | 0.66 | MGLL (0.85) | MGLLHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | MGLL 2345/4885HSD11B1 785/4885SLC18A3 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.